Vertex Pharmaceuticals Incorporated logo

Vertex Pharmaceuticals Incorporated (VRTX)

Market Open
1 Apr, 20:00
MX$
9,845. 23
-234.11
-2.32%
MX$
- Market Cap
30.83 P/E Ratio
0% Div Yield
322 Volume
14.94 Eps
MX$ 10.08K
Previous Close
Day Range
9,845.23 9,845.23
Year Range
6,530.25 10,477.52
Earnings results expected in 33 days

Summary

VRTX trading today lower at MX$9.85K, a decrease of 2.32% from yesterday's close, completing a monthly increase of 0.39% or MX$37.97. Over the past 12 months, VRTX stock gained 17.92%.
VRTX is not paying dividends to its shareholders.
The last earnings report, released on Feb 03, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on May 05, 2025.
The stock of the company had never split.
The company's stock is traded on 11 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Want to track VRTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

VRTX Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.

Vertex Pharmaceuticals Incorporated Dividends

VRTX is not paying dividends to its shareholders.

Vertex Pharmaceuticals Incorporated Earnings

5 May 2025 (33 Days) Date
-
Cons. EPS
-
EPS
3 Feb 2025 Date
-
Cons. EPS
-
EPS
4 Nov 2024 Date
-
Cons. EPS
-
EPS
1 Aug 2024 Date
-
Cons. EPS
-
EPS
30 Jul 2024 Date
-
Cons. EPS
-
EPS
VRTX is not paying dividends to its shareholders.
5 May 2025 (33 Days) Date
-
Cons. EPS
-
EPS
3 Feb 2025 Date
-
Cons. EPS
-
EPS
4 Nov 2024 Date
-
Cons. EPS
-
EPS
1 Aug 2024 Date
-
Cons. EPS
-
EPS
30 Jul 2024 Date
-
Cons. EPS
-
EPS

Vertex Pharmaceuticals Incorporated (VRTX) FAQ

What is the stock price today?

The current price is MX$9,845.23.

On which exchange is it traded?

Vertex Pharmaceuticals Incorporated is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is VRTX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on May 05, 2025.

Has Vertex Pharmaceuticals Incorporated ever had a stock split?

No, there has never been a stock split.

Vertex Pharmaceuticals Incorporated Profile

Biotechnology Industry
Healthcare Sector
Dr. Jeffrey Marc Leiden M.D., Ph.D. CEO
XMEX Exchange
US92532F1003 ISIN
US Country
5,400 Employees
- Last Dividend
24 Aug 2000 Last Split
24 Jul 1991 IPO Date

Overview

Vertex Pharmaceuticals Incorporated stands at the forefront of biotechnology innovation, focusing its efforts on the development and commercialization of therapies aimed at treating cystic fibrosis (CF), a debilitating genetic disorder. Since its establishment in 1989, the company has been pioneering in its approach to providing groundbreaking treatments that significantly improve the lives of those affected by CF. Operating from its headquarters in Boston, Massachusetts, Vertex extends its impact globally through the marketing of its advanced therapeutic solutions. Beyond cystic fibrosis, the company's research pipeline explores treatments for a variety of serious conditions including pain management, sickle cell disease, beta thalassemia, focal segmental glomerulosclerosis, Type 1 Diabetes, and cancer. Vertex's commitment to innovation is further underscored by its strategic collaborations with leading biotech entities such as CRISPR Therapeutics AG, Moderna, Inc., and several others, aiming to harness cutting-edge science in the development of novel therapies.

Products and Services

  • TRIKAFTA/KAFTRIO: Marketed for individuals with CF aged 2 years and older possessing at least one F508del mutation. This therapy represents a significant breakthrough in CF treatment, targeting the underlying genetic cause of the disease.
  • SYMDEKO/SYMKEVI: Available for CF patients aged 6 years and older. This treatment option provides an alternative for those seeking effective management of their CF symptoms.
  • ORKAMBI: Approved for CF patients 1 year of age or older. ORKAMBI addresses specific genetic mutations associated with CF, providing patients and their families hope for a better quality of life.
  • KALYDECO: Designed for patients 1 year of age or older who have CF with the ivacaftor mutation. KALYDECO was the first medication to treat the underlying cause of CF in patients with specific mutations.
  • VX-522: A CFTR mRNA therapeutic currently in Phase 1 clinical trials aimed at addressing the root cause of CF across a broader patient population.
  • VX-548: A non-opioid medication for the treatment of acute and neuropathic pain, now in Phase 3 clinical trials, highlighting Vertex's dedication to addressing the widespread issue of pain management.
  • Exa-cel: In Phase 2/3 clinical trials, this innovative treatment is being developed for sickle cell disease and transfusion-dependent beta thalassemia, promising hope for patients with these challenging conditions.
  • Inaxaplin: Targeting APOL1-mediated focal segmental glomerulosclerosis and associated comorbidities like hypertension, this potential therapy is in a unified Phase 2/3 study.
  • VX-880 and VX-264: Representing Vertex's foray into the treatment of Type 1 Diabetes, these candidates are in Phase 1/2 clinical trials, exploring new frontiers in diabetes care.
  • VX-970: This candidate is in Phase 2 clinical trials for the treatment of cancer, reflecting Vertex's commitment to expanding its impact beyond CF.
  • VX-803 and VX-984: Both in Phase 1 clinical trials, these treatments are part of Vertex's burgeoning cancer therapy portfolio, seeking to offer novel solutions for cancer patients.

Contact Information

Address: 50 Northern Avenue, Boston, MA, United States, 02210
Phone: 617 341 6100